1 Tarr P, Baumann K, Wallnöfer A, Zimmerli F, Maritz D, Burri U, et al. Akute Harnwegsinfektionen, Teil 1: HWI in der Praxis. Swiss Medical Forum – Schweizerisches Medizin-Forum. 2013; 13(24):467–471. 10.4414/smf.2013.01543
2 Kronenberg A, Bütikofer L, Odutayo A, Mühlemann K. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ. 2017. 10. 10.1136/bmj.j4784
3 Moore M, Trill J, Simpson C, Webley F, Radford M, Stanton L, et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection. 2019; 25(8):973–980. 10.1016/j.cmi.2019.01.011
Literatur
1 Brumbaugh AR, Mobley HL. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine. Expert Review of Vaccines. 2012;11(6):663–76. 10.1586/erv.12.36.
2 Hooton TM. Uncomplicated Urinary Tract Infection. N Engl J Med. 2012;366(11):1028–37. 10.1056/NEJMcp1104429.
3 Datta R, Juthani-Mehta M. Nitrofurantoin vs Fosfomycin: Rendering a Verdict in a Trial of Acute Uncomplicated Cystitis. JAMA. 2018;319(17):1771. 10.1001/jama.2018.4654.
4 Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, et al. Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial. JAMA Internal Medicine. 2018;178(11):1509–15. 10.1001/jamainternmed.2018.4204.
5 Little P, Moore MV, Turner S, Rumsby K, Warner G, Lowes JA, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ. 2010;340(feb05 1):c199–c199. 10.1136/bmj.c199.
6 Tarr P, Baumann K, Wallnöfer A, Zimmerli F, Maritz D, Burri U, et al. Akute Harnwegsinfe ktionen, Teil 1: HWI in der Praxis. Swiss Medical Forum – Schweizerisches Medizin-Forum. 2013;13(24):467–71. 10.4414/smf.2013.01543.
7 Schwenke J, Schaub R, Tarr P. Update Antibiotikaresistenzen 2018 für die Praxis. Primary and Hospital Care: Allgemeine Innere Medizin. 2018;376–80:10.4414/phc-d.2018.01839.
8 Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clinical Infectious Diseases. 2011;52(5):e103–e120. 10.1093/cid/ciq257.
9 Hasse B, Huttner A, Huttner B, Egger M, Zanetti G, Marschall J, et al. Behandlung von unkomplizierten Harnwegsinfektionen. 2014; . Available from:
https://www.researchgate.net/publication/278748193_Behandlung_von_unkomplizierten_Harnwegsinfektionen10.5167/uzh-106675.
10 Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, et al. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018;319(17):1781–9. 10.1001/jama.2018.3627.
11 Wijma RA, Koch BCP, Gelder T van, Mouton JW. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers. Clinical Microbiology and Infection. 2018;24(5):528–32. 10.1016/j.cmi.2017.08.023.
12 Palou J, Angulo J, Ramón de Fata F, García-Tello F, González-Enguita C, Boada A, et al. Randomized comparative study for the assessment of a new therapeutic schedule of fosfomycin trometamol in postmenopausal women with uncomplicated lower urinary tract infection. Actas Urológicas Españolas. 2012;37(3):147–155. 10.1016/j.acuro.2012.06.007.
13 Qiao L-D, Zheng B, Chen S, Yang Y, Zhang K, Guo H-F, et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open. 2013;3(12):e004157. 10.1136/bmjopen-2013-004157.
14 Giancola S, Mahoney M, Hogan M, Raux B, McCoy C, Hirsch E. Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes. Chemotherapy. 2017;62(2):100–4. 10.1159/000449422.
15 Kronenberg A, Bütikofer L, Odutayo A, Mühlemann K. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ. 2017;10. 10.1136/bmj.j4784.
16 Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Frontiers in Microbiology [Internet]. 2016 [cited 2019 Apr 7]; 6. Available from:
http://journal.frontiersin.org/Article/10.3389/fmicb.2015.01543/abstract10.3389/fmicb.2015.01543.
17 Caballero S, Carter R, Ke X, Sušac B, Leiner IM, Kim GJ, et al. Distinct but Spatially Overlapping Intestinal Niches for Vancomycin-Resistant Enterococcus faecium and Carbapenem-Resistant Klebsiella pneumoniae. Baumler AJ, editor. PLOS Pathogens. 2015;11(9):e1005132. 10.1371/journal.ppat.1005132.
18 Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Medicine. 2016;8(1):39. 10.1186/s13073-016-0294-z.
19 Knottnerus BJ, Geerlings SE, Moll van Charante EP, Riet G ter. Women with symptoms of uncomplicated urinary tract infection are often willing to delay antibiotic treatment: a prospective cohort study. BMC Family Practice. 2013;14(1):71. 10.1186/1471-2296-14-71.
20 Harbarth S, Balkhy HH, Goossens H, Jarlier V, Kluytmans J, Laxminarayan R, et al. Antimicrobial resistance: one world, one fight! Antimicrob Resist Infect Control. 2015;4(1):49. 10.1186/s13756-015-0091-2.
21 World Health Organization, editor. Antimicrobial resistance: global report on surveillance [Internet]. Geneva, Switzerland: World Health Organization; 2014. Available from:
https://www.who.int/drugresistance/documents/surveillancereport/en/.
22 Vollaard EJ, Clasener HA. Colonization Resistance. Antimicrobial Agents and Chemotharpy. 1994. 10.1128/AAC.38.3.409.
23 Stewardson AJ, Gaïa N, François P, Malhotra-Kumar S, Delémont C, Martinez de Tejada B, et al. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. Clinical Microbiology and Infection. 2015;21(4):344.e1-344.e11. 10.1016/j.cmi.2014.11.016.
24 Aragón IM, Herrera-Imbroda B, Queipo-Ortuño MI, Castillo E, Del Moral JS-G, Gómez-Millán J, et al. The Urinary Tract Microbiome in Health and Disease. European Urology Focus. 2018;4(1):128–38. 10.1016/j.euf.2016.11.001.
25 Whiteside SA, Razvi H, Dave S, Reid G, Burton JP. The microbiome of the urinary tract—a role beyond infection. Nature Reviews Urology. 2015;12(2):81–90. 10.1038/nrurol.2014.361.
26 Leydon GM, Turner S, Smith H, Little P, on behalf of the UTIS team. Women’s views about management and cause of urinary tract infection: qualitative interview study. BMJ. 2010;340(feb05 1):c279–c279. 10.1136/bmj.c279.
27 Mangin D. How doctors deliver care is as influential as the treatment itself. BMJ. 2010;340:373–374. 10.1136/bmj.c657.
28 Finucane TE. ‘Urinary Tract Infection’ and the Microbiome. The American Journal of Medicine. 2017;130(3):e97–e98. 10.1016/j.amjmed.2016.08.018.
29 Tarr P, Baumann K, Wallnöfer A, Zimmerli F, Maritz D, Burri U, et al. Akute Harnwegsinfektionen, Teil 2: HWI im Spital sowie Alters- und Pflegeheim. Swiss Medical Forum – Schweizerisches Medizin-Forum. 2013;472–5. 10.4414/smf.2013.01546.
30 Cai T, Mazzoli S, Mondaini N, Meacci F, Nesi G, D’Elia C, et al. The Role of Asymptomatic Bacteriuria in Young Women With Recurrent Urinary Tract Infections: To Treat or Not to Treat? Clinical Infectious Diseases. 2012;55(6):771–7. 10.1093/cid/cis534.
31 Nicolle LE, Gupta K, Bradley SF, Colgan R, DeMuri GP, Drekonja D, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clinical Infectious Diseases. 2019;68. 10.1093/cid/ciy1121.
32 Pearce MM, Zilliox MJ, Rosenfeld AB, Thomas-White KJ, Richter HE, Nager CW, et al. The female urinary microbiome in urgency urinary incontinence. American Journal of Obstetrics and Gynecology. 2015;213(3):347.e1-347.e11. 10.1016/j.ajog.2015.07.009.
33 Thomas-White KJ, Kliethermes S, Rickey L, Lukacz ES, Richter HE, Moalli P, et al. Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence. American Journal of Obstetrics and Gynecology. 2017;216(1):55.e1-55.e16. 10.1016/j.ajog.2016.07.049.
34 Betschart C, Albrich W, Brandner S, Faltin D, Kuhn A, Surbek D, et al. Akute und rezidivierende Harnwegsinfektionen [Internet]. 2018. Available from:
https://www.sggg.ch/fileadmin/user_upload/58_Harnwegsinfekt_Juni_2018.pdf.
35 Deutsches Ärzteblatt: EMEA schränkt Anwendung von Moxifloxacin und Norfloxacin deutlich ein [Internet]. Deutsches Ärzteblatt. 2012. Available from:
https://www.aerzteblatt.de/nachrichten/51270/Leberschaeden-durch-Moxifloxacin-und-Levofloxacin.
36 European Medicines Agency. EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections [Internet]. 2008. Available from:
https://www.ema.europa.eu/en/news/emea-recommends-restricted-use-oral-norfloxacin-containing-medicines-urinary-infections
37 Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015; :h6544. 10.1136/bmj.h6544.
38 Vik I, Bollestad M, Grude N, Bærheim A, Damsgaard E, Neumark T, et al. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—A double-blind, randomized non-inferiority trial. Basu S, editor. PLOS Medicine. 2018;15(5):e1002569. 10.1371/journal.pmed.1002569.
39 Moore M, Trill J, Simpson C, Webley F, Radford M, Stanton L, et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clinical Microbiology and Infection. 2019;25(8):973–80. 10.1016/j.cmi.2019.01.011.
40 Hofmann Y, Berger H, Wingeier B, Huber B, Boggian K, Hug-Batschelet H, et al. Behandlung der Streptokokken-Angina. Swiss Medical Forum – Schweizerisches Medizin-Forum. 23.
41 Little P. Antibiotics or NSAIDs for uncomplicated urinary tract infection? BMJ. 2017;j5037. 10.1136/bmj.j5037.
42 Wojnicz D, Kucharska AZ, Sokół-Łętowska A, Kicia M, Tichaczek-Goska D. Medicinal plants extracts affect virulence factors expression and biofilm formation by the uropathogenic Escherichia coli. Urol Res. 2012;40(6):683–97. 10.1007/s00240-012-0499-6.
43 Mutters NT, Mampel A, Kropidlowski R, Biehler K, Günther F, Bălu I, et al. Treating urinary tract infections due to MDR E. coli with Isothiocyanates – a phytotherapeutic alternative to antibiotics? Fitoterapia. 2018;129:237–40. 10.1016/j.fitote.2018.07.012.
44 Marcon J, Schubert S, Stief CG, Magistro G. In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections. Infection [Internet]. 2019 [cited 2019 Nov 10]; . Available from:
http://link.springer.com/10.1007/s15010-019-01315-410.1007/s15010-019-01315-4.
45 Garcia Larrosa A, Alexe O. Efficacy and Safety of a Medical Device versus Placebo in the Early Treatment of Patients with Symptoms of Urinary Tract Infection: A Randomized Controlled Trial. Clin Microbiol [Internet]. 2016 [cited 2019 Nov 10]; 05(01). Available from:
http://www.esciencecentral.org/journals/efficacy-and-safety-of-a-medical-device-versus-placebo-in-the-earlytreatment-of-patients-with-symptoms-of-urinary-tract-infection-2327-5073-1000233.php?aid=6702110.4172/2327-5073.1000233
46 Albrecht U, Goos K-H, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Current Medical Research and Opinion. 2007;23(10):2415–22. 10.1185/030079907X233089.
47 Wagenlehner FM, Abramov-Sommariva D, Höller M, Steindl H, Naber KG. Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urol Int. 2018;101(3):327–36. 10.1159/000493368.
48 Vicariotto F. Effectiveness of an Association of a Cranberry Dry Extract, D-mannose, and the Two Microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in Women Affected by Cystitis: A Pilot Study. Journal of Clinical Gastroenterology. 2014;48:S96–S101. 10.1097/MCG.0000000000000224.
49 Del Popolo G, Nelli F. Recurrent bacterial symptomatic cystitis: A pilot study on a new natural option for treatment. Arch Ital Urol Androl. 2018;90(2):101. 10.4081/aiua.2018.2.101.
50 Cai T, Tiscione D, Cocci A, Puglisi M, Cito G, Malossini G, et al. Hibiscus extract, vegetable proteases and Commiphora myrrha are useful to prevent symptomatic UTI episode in patients affected by recurrent uncomplicated urinary tract infections. Arch Ital Urol Androl. 2018;90(3):203. 10.4081/aiua.2018.3.203.
51 Little P, Merriman R, Turner S, Rumsby K, Warner G, Lowes JA, et al. Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ. 2010;340(feb05 1):b5633–b5633. 10.1136/bmj.b5633.
52 Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S, Rottensterich E, et al. Recurrent Urinary Tract Infections in Postmenopausal Women. Clinical Infectious Diseases. 2000;30(1):152–6. 10.1086/313596.
53 Foxman B, Somsel P, Tallman P, Gillespie B, Raz R, Colodner R, et al. Urinary tract infection among women aged 40 to 65: Behavioral and sexual risk factors. Journal of Clinical Epidemiology. 2001;9. 10.1016/s0895-4356(00)00352-8.
54 Gharbi M, Drysdale JH, Lishman H, Goudie R, Molokhia M, Johnson AP, et al. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. BMJ. 2019;l525. 10.1136/bmj.l525.
55 Beetz R. Mild dehydration: a risk factor advertising and analytics partners in accordance with our Privacy Policy. You can manage your of urinary tract infection? preferences in “Manage Cookies”. European Journal of Clinical Nutrition. 2003;57:52–8. 10.1038/sj.ejcn.1601902.
56 Vyas S, Varshney D, Sharma P, Juyal R, Nautiyal V, Shrotriya V. An overview of the predictors of symptomatic urinary tract infection among nursing students. Ann Med Health Sci Res. 2015;5(1):54–8. 10.4103/2141-9248.149790.
57 Grady D. Drinking More Water for Prevention of Recurrent Cystitis. JAMA Intern Med. 2018;178(11):1515. 10.1001/jamainternmed.2018.4195.